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Conclusions: ABSI couldn’t predict the new onset of hypertension in Chinese adult
population from Chengdu community during 15-years follow up, while BMI/ WC
could.
GW25-e2117
Investigation of the prevalence of obstructive sleep apnea hypopnea syndrome
and cardiovascular disease in the population of Navy veteran who is older
than or equal to 60 years old
Yin Zhong, Yang Ye
Department of Cardiology, Navy General Hospital
Objectives: To investigate the prevalence of obstructive sleep apnea hypopnea syn-
drome (0SAS) and cardiovascular disease in the population of Navy veteran who is
older than or equal to 60 years old.
Methods: There are 1961 Navy veteran who is older than or equal to 60 years old
were inrolled. Everyone ﬁnished the standardized questionnaire. Polysomnography
(PSG), ordinary and/or dynamic electrocardiogram, blood pressure and coronary
angiography was performed for each one.
Results: In all 1961 people, 531 (27.1%) people have OSAS, 366 (18.7%) people with
coronary heart disease (CHD), 67 (3.4%) people with chronic heart failure (CHF), 323
(16.5%) people with diabetes. Of 531 OSAS patients, 235 (44.3%) patients with CHD,
322 (60.66%) complicated with hypertension, 271 (51.04%) had arrhythmia, 36
(6.8%) patients with CHF, 228 (42.9%%) patients with diabetes. At the same time,
among 1430 non-OSAS people, 131 (9.2%) people with CHD, 31 (2.2%) people with
CHF, 95 (6.6%) people with diabetes. At the same time, our data show that obese, high
BMI (kg/m2) and neck circumference (CM) were risk factors for OSAS, and the risk
of cardiovascular of cardiovascular disease increased with the severity of OSAS.
Conclusions: The prevalence of OSAS and cardiovascular disease were signiﬁcantly
increased among Navy veteran who is older than or equal to 60 years old. The
prevalence of cardiovascular disease in patients with OSAS was signiﬁcantly higher
than that of non-OSAS people. And prove that obese, high BMI (kg/m2) and neck
circumference (CM) were risk factors for OSAS, and the risk of cardiovascular of
cardiovascular disease increased with the severity of OSAS.
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Renal function decline has a different effect on predicting CVD risk in various
populations- a Chinese longitudinal study
Jin Bo1, Han Lulu1, Zhang Weiguang2, Chen Xiang-Mei2, Bai Xiaojuan1
1Shenjing Hospital of China Medical University, 2General Hospital of Chinese
People’s Liberation Army
Objectives: Chronic kidney disease (CKD) is generally considered an independent
risk factor for cardiovascular disease (CVD) development, but rates in individuals
with estimated glomerular ﬁltration rate (eGFR)>60 ml/min/1.73 m2 are uncertain.
The purpose of this study was to examine the association exists between eGFR and
Framingham global CVD risk score (FRS) in a Chinese population with no CKD or
CVD.
Methods: A total of 333 participants were divided into three groups based on
FRS. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
and CKD-EPI equation for Asians (CKD-EPI-ASIA) were used to measure eGFR.
Results: A signiﬁcant inverse association between eGFR and FRS was conﬁrmed with
Pearson correlation coefﬁcients of -0.669, -0.698 (eGFRCKD-EPI, P<0.01) and -0.658,
-0.690 (eGFRCKD-EPI-ASIA, P<0.01). This association gradually diminished with
progression from the low- to high-risk groups (eGFRCKD-EPI, r¼-0.615, -0.282,
-0.197, P<0.01, P<0.01, P>0.05; similar results according to the CKD-EPI-ASIA
equation). In the low- or moderate-risk new-groups, this association became stronger
with increased FRS (eGFRCKD-EPI-ASIA, r¼-0557, -0.622 or -0.326, -0.329, P<0.01).
In contrast to the results from 2008, eGFR was independently associated with FRS
following adjustment for traditional cardiovascular risk factors (P<0.05).
Conclusions: Renal function has a different effect on predicting CVD risk in various
populations. With increasing FRS and decreasing eGFR, it is also independently
associated with CVD, even in individuals with eGFR>60 ml/min/1.73 m2.
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Prevention of Cardiovascular Disease in HIV-Infected Patients
Ning Jiang, Myat Soe, Linda Green
Prince George’s Hospital Center
Objectives: World Health Organization (WHO) estimates that cardiovascular disease
(CVD) and human immunodeﬁciency virus (HIV) will top the causes for global mor-
tality and disability in 2030. How to develop and implement effective primary pre-
vention strategy in HIV-infected patients with high cardiovascular risk is of paramount
importance. We conduct this retrospective study to assess cardiovascular risk and
implement prophylactic strategy as well as aspirin use in patients with HIV infection.
Methods: Federally-funded Ryan White program helps coordinate comprehensive
medical care for uninsured HIV-infected patients. The medical records of 115
consecutive HIV-infected adults (>18 years old) from January to December 2012
were reviewed. Multiple variables of socio-demographic characteristics, laboratory
ﬁndings and treatment were collected. Framingham risk score (FRS) was calculated to
assess 10-year cardiovascular risk, and D:A:D score based on traditionalJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/Ecardiovascular risk factors as well as HIV-speciﬁc factors was calculated to assess 5-
year cardiovascular risk.
Results: A total of 115 HIV-infected individuals (mean age: 44.5 years) were included
in this cross-sectional study. In federally funded Ryan White program, the prevalence
of cardiovascular risk factors were markedly higher than those in D:A:D study,
notably hypertension (32.2 vs 7.2), obesity (23.8 vs 4.8), and diabetes (9.6 vs 2.8).
The proportion of HIV-infected patients with low, intermediate and high cardiovas-
cular risk were 65.2%, 20.0% and 14.8% using FRS, while 44.3%, 47.0% and 8.7%
using D:A:D prediction. Further analysis showed that FRS, D:A:D and stroke risk
score correlated well. Even if we implement appropriate approach ensuring that no
progression of the underlying risk factors, patients with high cardiovascular risk are
estimated to be doubled in the next 10 years. After screening with the United States
Prevention Services Task Force (USPSTF) recommended criteria, 57 patients (52.8%)
should be on aspirin for primary prevention of CVD. However, only 9.3% of the
patients use aspirin as primary prevention of CVD.
Conclusions: In this newly insured HIV/AIDS population, cardiovascular risk is
consistently high estimated for various diseases in different time horizons which might
reﬂect the high prevalence of risk factors. An effective intervention strategy to reduce
CVD burden requires more active identiﬁcation and more aggressive management of
traditional and HIV-speciﬁc cardiovascular risks.
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Outdoor air pollution and hospital emergency room visit for stroke in a Chinese
southern city
Huang Zhijun1,2, Zhou Yuqing1, Lu Yao1,2, Yuan Hong1,2, Tang Xiaohong1,2,
Lu Chan2, Deng Qihong2, Duan Yizhu1,2
1The Third Xiangya Hospital, Central South University, 2The Institute of
Environmental Health, Central South University
Objectives: We investigated the relationship between daily changes in atmospheric
pollutants and hospital emergency room visit (ERV) for stroke.
Methods: Data of daily hospital ERV for stroke and atmospheric pollutants in
Changsha city between 2008 and 2009 were collected. Using a time-stratiﬁed case-
crossover design we built generalized linear Poisson models to analyze association
between atmospheric pollutant and stroke incidence in cold season (December-April)
and warm season (May-November).
Results: We found sulfur dioxide was signiﬁcantly associated with TIA (P<0.05) in
lags of 0, 1, 3 days in cold seasons. A 10mg/m3 increase of PM10 was signiﬁcantly
associated with ERV for cerebra hemorrhage (OR, 1.466; 95% CI, 1.139-1.887) in lag
1 day in cold season. Atmospheric pollutants were not associated with ERV for ce-
rebral infarction (P>0.05).
Conclusions: This study demonstrates Changes of atmospheric sulfur dioxide levels
in Changsha is signiﬁcantly associated with stroke incidence in cold seasons.Prevention of Cardiovascular DiseaseGW25-e2337
Prevalence of risk factors and performance of evidence-based medicine among
hospitalized patients with acute coronary syndromes - Results from the Bridging
the Gap on CHD Secondary Prevention in China (BRIG) project
Wang Wei, Zhao Dong, Liu Jun, Qi Yue, Sun Jiayi, Liu Jing
Department of Epidemiology, Beijing An Zhen Hospital, Capital Medical University,
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Objectives: To analyze the distribution of multiple risk factors for hospitalized pa-
tients with acute coronary syndromes (ACS) and explore the status and determinants
of evidence-based performance.
Methods: This was a multi-center cross-sectional study based on 34 hospitals from
22 provinces of China. From each hospital, more than 90 ACS patients were
consecutively enrolled since April 15, 2012 according to a standard protocol. A
total of 3253 patients with complete data were eligible for the ﬁnal analysis in this
study.
Results: (1) The mean age of male patients with ACS was lower than that of female
patients (60.4 years vs 66.2 years, P<0.01). Nearly 60% of ACS patients were under
65-years old. Early onset of ACS accounted for a quarter of male patients (< 55
years of age) and two-thirds of female patients (< 65 years old). (2) Of four ACS
major risk factors including hypertension, hyperlipidemia, smoking and diabetes,
more than 90% of ACS patients had one or more risk factors and of those about two-
thirds of patients had two or more risk factors. The prevalence of hypertension was
the highest (68.4%), followed by smoking rate in males (42.7%), or hyperlipidemia
rate in females (44.5%). (3) The proportion of PCI treatment was higher in male
patients than female patients (57.5% vs 42.0%, P<0.01). As for the application of
evidence-based drugs, 95.3% of ACS patients took aspirin, which is the most
commonly used drug. The second was statin (90.1%). The lowest was ACEI or ARBpidemiology, Prevention and Control C103
(53.6%). Multivariable analysis suggested that PCI treatment was the important
inﬂuential factors of usage rates of evidence-based drugs in secondary prevention.
The results showed that the nonuse rates of evidence-based drugs were 30% higher
for ACEI or ARB and b receptor blockers, 60% higher for statins, and 5-7 times
higher for antiplatelet agents in ACS patients without PCI treatment than those with
PCI treatment.
Conclusions: In China, more than 90% of hospitalized patients with ACS had one or
more major risk factors. There is still scope for improvement in the application of
drugs recommended by guidelines, especially for ACS patients without PCI
treatment.
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Analysis of aspirin regimen of general practitioners for patients with Coronary
Heart Disease or Ischemic Cerebrovascular Disease in Beijing
Zuo Huijuan, Liu Jing, Wang Jinwen, Liu Jun, Wang Miao
Beijing Institute of Heart, Lung & Blood Vessel Diseases, Beijing Anzhen Hospital
afﬁliated to the Capital University of Medical Sciences
Objectives: Aspirin can signiﬁcantly decrease the risk of recurrence events for pa-
tients with cardiovascular disease (CVD), while PURE study indicated only few in-
dividuals with CVD took aspirin (15.5%) in communities of China. So a project
initiated by Beijing Municipal Health Bureau to assess the key knowledge on aspirin
use for GPs and the real statue of antithrombolic therapy in communities in Beijing.
Methods: This cross-sectional study was conducted in 10 community health centers
from 10 different districts in Beijing. A total of 207 GPs were recruited to collect the
key knowledge about aspirin use. 459 patients aged 30 to 89 years who visited the
GPs from the later August to the later September were identiﬁed as CHD and ICVD. A
standardized regimen questionnaire and key knowledge questionnaire was ﬁnished by
physicians.
Results: 312 patients (70%) were prescribed aspirin by GPs, it was high in patients
with unstable angina (80.8%), and low in patients with TIA (60.4%). Patients with
Ischemic stroke, stable angina, after bypass surgery or PCI, both CHD and ICVD
had the similar rate in 69.8%, 65.4%, 65.2% and 70.1%. 147 patients were not
prescribed aspirin, among them, 60 patients (40.8%) had a rest of medicine, 43
patients (29.3%) were thought as no need to use aspirin by GPs, and 30(20.4%)
patients were worried about its side-effects. Other reasons included gastrointestinal
reaction, light bleeding, peptic ulcer and high level BP. The utility rate of aspirin
was 80.0% (372/459). It was 84.1% in patients with CHD, 86.2% in patients with
Ischemic stroke, 77.9% in patients with both CHD and ICVD, and 60.4% in pa-
tients with TIA. It was lower in patients both with CHD and ICVD than patients
with CHD only, so advanced analysis was conducted in total of 17 patients with
CHD and ICVD no use aspirin; there were 6 (35.2%) patients because of worrying
about side-effects or being thought as no need to take aspirin by GPs. We also
analyzed the reasons why patients with TIA didn’t take aspirin, 10 (47.6%) pa-
tients were thought as no need to take aspirin by GPs and 11 (52.4%) patients were
worried about side-effects. Most of GPs knew patients with ACS, CHD and
Ischemic stroke should use aspirin with the percentage of 94.2%, 89.4% and
97.1%, but only 65.7% of GPs knew patients with TIA should use aspirin also.
Dosage regimen: The dosage of aspirin was 100 mg daily for all patients on the
prescription. About half of doctors suggested their patients taking medicine after
meal, 5.8% of doctors did not give any suggestion, and 2.9% of doctors did not
know how to give suggestion. About half (52.7%) of doctors suggested their
patients taking medicine on evening.
Conclusions: The rate of aspirin use was relative high in patients visiting the general
practitioners normally. The dosage of aspirin was rational. GPs’ knowledge and
adherence to the guideline played an important role on the utility rate of aspirin
especially in patients with TIA and stable angina.
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Investigation of coronary heart disease secondary prevention and standardized
follow-up
Gong Yanjun, Yang Fan, Huo Yong, Hong Tao
Peking University ﬁrst hospital
Objectives: To reveal the current status and effectiveness of follow-up on secondary
prevention of coronary heart disease (CHD) at Peking University First Hospital.
Methods: The study population was from Peking University First Hospital, one of
19 hospitals in the eleventh 5-year national key technologies R&D program for
coronary heart disease (CHD) secondary prevention research. This study of CHD
secondary prevention, conducted in China, aimed to standardize management of
CHD secondary prevention and improve adherence to secondary prevention guide-
lines and regular follow-up. The study group comprised 496 patients diagnosed with
CHD from January 1, 2007 to December 31, 2009 after a standardized follow-up
program began. A group of 300 CHD patients diagnosed with CHD from January 1,
2004 to December 31, 2004 were evaluated as control group. Study group partici-
pants were followed-up every 3 months for at least 1 year in the outpatient
department and interviewed by telephone from November 2012 to January 2013.
Data on control of risk-factors, medical therapy, and clinical events were collected.
Risk factors control and medications were compared between study group and
control group.
Results: Of the 496 patients enrolled in study group, 360 were male (72.6%), and the
age was 63.510.2 years (range, 24-85 years). The average duration of follow-up wasC104 JACC Vol 64/16/Suppl C j October 164.6 years (range, 3.5-6.0 years). At discharge, 75.4% of study group patients had
ceased smoking, 51.4% exercised regularly, 42.4% were overweight, 56.7% had blood
pressure <140/90 mmHg (<130/80 in those with diabetes mellitus), 51% had serum
low-density-lipoprotein cholesterol <2.60 mmol/L and 64.2% had fasting plasma
glucose <6.11 mmol/L. Antiplatelet medication was used by 99.4% of study group
patients, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers by
64.5%, beta-blockers by 79.1%, and statins by 94.3%. Major adverse cardiac events
(MACEs), the primary clinical outcome, occurred in 22.7% at the end of follow-up.
The proportions of quitting smoking (82.2% vs 73.7%, P¼0.014), control of serum
lipids (84.4% vs 45.6%, P¼0.000) and statin use (92.5% vs 54.3%, P¼0.000) at the
end of follow-up were signiﬁcantly greater in the study group than in the control
group.
Conclusions: Although a standardized follow-up program improved CHD secondary
prevention, some CHD patients still did not achieve the goals of lifestyle change, risk
factor control, and medication therapy.
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Aquired Long QT Syndrome May Contribute to the All Cause Mortality in
Hospitalized Patients-A Pilot Study
Yu Haixu1, Liu Jinqiu1, Liu Ying1, Zhang Yanli1, Xu Fei1, Zhou Yu1, Li Pinrui1,
Gou Cheng1, Guan Xumin1, Wang Binhao1, Khalid Bin Waleed1, Yang Yanzong1,
Zhang Li2, Xia Yunlong1
1Department of Cardiology, First Afﬁliated Hospital of Dalian Medical University
Dalian, China, 2Center for Clinical Cardiology, Lankenau Institute for Medical
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Objectives: Though it is well-known that markedly prolonged QT interval (QTc500
ms) is an independent risk factor for sudden death and a predictor for all-cause car-
diovascular mortality and stroke, acquired QT syndrome (ALQTS) in the hospital
setting has long been overlooked.This study is to determine the prevalence of
QTc500 ms in hospitalized patients and their outcomes.
Methods: Electronic Medical Records of all hospitalized patients in one study center
were retrieved from January 1-21, 2014 with the inclusion criterion of QTc500 ms
and QRS duration 120 ms. Clinical evaluation included the diagnosis, presence of
electrolyte imbalance, renal dysfunction, the use of QT prolonging drugs and
outcomes.
Results: QTc500 ms was found in 2.6% (106/4121) of hospitalized patients. Among
them (age 66.614.4 years, female 58%), 71% were admitted to non-cardiology
departments. The use of diuretics and QT prolonging drugs (1) were seen in 51%
and 38%. Hypokalemia (serum K+<3.5 mmol/L ) was present in 33% and hypocal-
cemia (serum Ca2+<2.1mmol/L ) in 55%, respectively. In the ALQTS cohort, 7.5%
developed syncope/life-threatening arrhythmias and the 3-month all-cause mortality
was 13%. In latter, hypocalcemia was present 71% (10/14).
Conclusions: ALQTS with markedly prolonged QT intervals is 52 times higher
(2.6%) than that of congenital form (0.05%). In the hospital setting the majority of
ALQTS is seen in non-cardiology serves. The 3-month all-cause mortality is up to
13% in the ALQTS cohort. Hypocalcemia is the most common electrolyte imbalance
in patients with the worst outcome. Further investigation is underway to determine
whether a hospital-wide QTc500 ms alert system could prevent life-threatening
arrhythmia and sudden death in inhospital patients.
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Pentraxin-3 is associated with long-term adverse cardiovascular events in
patients with chronic heart failure.
Liu Haibo1,2, Wang Chunming1, Yu Wangjun1, Liu Yanhong1, Fang Yu1,
Bao Yingchun1, Zhang Limei1, Cao Yong1, Ge Junbo2
1Department of Cardiology, Yinzhou People’s Hospital, Ningbo University,
2Department of Cardiology, Shanghai Institute of Cardiovascular Diseases,
Zhongshan Hospital, Fudan University
Objectives: Pentraxin-3 (PTX3) is a novel inﬂammatory marker and a member of
pentraxin superfamily including C-reactive protein (CRP) and PTX3 is thought to
be more speciﬁc to cardiovascular inﬂammation than CRP, but its long-term
prognostic value in patients with chronic heart failure remains unclear. This study
was to evaluate the long-term prognostic value of PTX3 in patients with chronic
heart failure.
Methods: A total of 406 consecutive patients with chronic heart failure were pro-
spectively enrolled in this study for clinical 2-year follow-up. Plasma levels of PTX3
were determined in the second morning after hospitalized. Adverse cardiovascular
events were monitored as endpoints, the major endpoints included all-caused death
and re-hospitalization for worsening heart failure, the secondary endpoints included
acute myocardial infarction, stoke and peripheral arterial embolism.
Results: 376 patients have been followed-up for 2-year, 171 patients experienced
adverse cardiovascular events. The levels of PTX3 were signiﬁcantly and positively
associated with the severity of heart failure according to NYHA class (P<0.01).
Plasma PTX3 levels in patients with adverse cardiovascular events were signiﬁ-
cantly higher than those without (3.9110.83 ng/ml .vs 3.0880.99 ng/ml;
P<0.01), and the cardiac event rate was higher in patients with increased PTX3
(median value 3.438 ng/ml) than patients below median value (63.5% .vs 27.3%;
P<0.01). A Kaplan-Meier analysis revealed that patients with increased PTX3
(3.438 ng/ml) had a higher risk for adverse cardiovascular events than those–19, 2014 j GW-ICC Abstracts/Epidemiology, Prevention and Control
